Curare Laboratory LLC

CourtUnited States Bankruptcy Court, W.D. Kentucky
DecidedAugust 1, 2022
Docket21-31588
StatusUnknown

This text of Curare Laboratory LLC (Curare Laboratory LLC) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, W.D. Kentucky primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Curare Laboratory LLC, (Ky. 2022).

Opinion

UNITED STATES BANKRUPTCY COURT WESTERN DISTRICT OF KENTUCKY LOUISVILLE DIVISION

) IN RE: ) ) Chapter 11 CURARE LABORATORY LLC ) ) Debtor ) Case No. 21-31588 )

MEMORANDUM OPINION

This matter is before the Court on the Debtor’s Expedited Motion to Remove Custodian and Restore Possession, Custody, and Control to Debtor (the “Custodian Removal Motion”), [D.E. 3], filed by Curare Laboratory LLC (“Curare,” or the “Debtor”), the Joint Motion to Dismiss Pursuant to 11 U.S.C. § 1112 (the “Dismissal Motion”), [D.E. 171], filed by Bluewater Toxicology, LLC (“Bluewater”), Solar Holdings Group, LLC (“Solar”), and Jennifer Bolus (“Bolus”) (together, the “Bluewater Parties”), and the Motion for Summary Judgment as to Debtor’s Motion to Restore (“Summary Judgment Motion”), [D.E. 181], filed by the Bluewater Parties. For the reasons set forth below, the Court GRANTS the Bluewater Parties’ Dismissal Motion without prejudice to refiling. I. FACTS AND PROCEDURAL HISTORY Background: This case arises out of a dispute over the majority ownership interest in Bluewater, a medical testing and diagnostics company that has realized significant revenue in recent years due to the high demand for its COVID-19 testing services. As detailed more fully below, Curare maintains that it holds an 80% ownership interest in Bluewater pursuant to a Securities Purchase Agreement (“Sale Agreement”) which the Debtor entered into with Solar in September of 2017. The Bluewater Parties counter that Curare failed to effectuate this 80% purchase of Bluewater because Curare immediately defaulted on the Sale Agreement. In response to this alleged default, Solar and Bolus filed a state court lawsuit (“State Court Litigation”) against Curare in December 2017 in an effort to restore its control of Bluewater and hold Curare

accountable for its alleged default and related misconduct. According to the Bluewater Parties, the State Court Litigation resulted in the appointment of a monitor over Bluewater and Curare, the restoration of control over Bluewater back to Solar and its principal, Bolus, and a divestment of Curare’s operations of Bluewater. As a result, the Bluewater Parties have filed the Dismissal Motion seeking to dismiss the bankruptcy, or to have this Court abstain1, on grounds that Curare no longer has any ownership or control over Bluewater pursuant to the state court orders, and accordingly has no basis for relief. Curare counters that,

because the state court orders are interim, non-final orders that remain subject to further proceedings, Curare still maintains ownership and control over Bluewater, and seeks to have the state court-appointed monitor removed. Additionally, the Bluewater Parties seek dismissal on grounds that Curare’s newly- appointed manager, Tyler Burke (“Burke”), was never properly appointed as the LLC’s manager, a process which required an 85% majority vote by its members under the express terms of Curare’s

operating agreement. Since the parties do not dispute that no such vote ever took place, the Bluewater Parties contend that Burke lacked the managerial authority to put the Debtor in bankruptcy, warranting dismissal of the case. Curare counters that the inclusion of any 85% majority vote provision in a subsequent version of the operating agreement was inadvertent, that

1 The Bluewater Parties have raised arguments in favor of mandatory abstention, permissive abstention, and abstention based on the Rooker-Feldman Doctrine, discussed further below. Curare did effectuate a change in managerial authority by having its former manager, Kevin Liske (“Liske”), name Burke as the newly-appointed manager2, and that Solar and Bolus, as creditors of the Debtor, lack standing to challenge the terms of Debtor’s operating agreement. Curare concludes that, as a result of that managerial change, Burke did in fact have the power to file

bankruptcy under the controlling operating agreement. In February of 2022, the Court conducted a three-day evidentiary hearing3 (“Evidentiary Hearing”) on the Custodian Removal Motion, Dismissal Motion, and the Summary Judgment Motion, as discussed in more detail below. Curare Formation and Sale Agreement (July 2017): Originally formed in 2013, Bluewater is a medical diagnostics company located in Mt. Washington, Kentucky, that provides laboratory services in the form of specimen collection, testing, and diagnostic services. Feb. 16 Tr. 23:10-12, 23:20-24:5. Solar, also formed in 2013, is a holding company co-owned by Bolus

and Dr. Praveen Arla (“Arla”) which was created to hold Bluewater shares. Feb. 16 Tr. 21:19- 22:3. Besides its shares in Bluewater, Solar has no other assets. Feb. 16 Tr. 22:4-6. Solar initially held 95% of Bluewater’s membership interests along with two other minority partners. Feb. 16 Tr. 23:13-19; 29:19-25. However, in July 2017, Bolus was approached by Charles “Junior” Johnson (“Johnson”) regarding the potential sale of Bluewater, and ultimately agreed to proceed with a purchase transaction with Johnson. Feb. 16 Tr. 26:22-24; 27:10-19; 29:1-6.

Shortly thereafter, on or about August 10, 2017, Curare was formed to be a toxicology lab that would partner with and purchase membership interests in Bluewater from Solar. See Feb. 15

2 As explained further below, Liske sold his membership interest in JJSquared, Curare’s largest equity holder, to Laboratory Investment Company, LLC, an entity co-owned by Burke, and in conjunction with that sale, Liske attempted to appoint Burke as Curare’s new manager.

3 The evidentiary hearing was transcribed resulting in three transcripts: February 15 Transcript (“Feb. 15 Tr.”), February 16 Transcript (“Feb. 16 Tr.”), and February 24 Transcript (“Feb. 24 Tr.”). See [D.E. 262, 263, 273]. Tr. 74:18-20. Contemporaneously, four additional, related companies were also created: (1) Curare Telehealth, LLC (“Telehealth”), a mobile telemedical company; (2) Curare Management, LLC (“Management”); (3) Curare Medical; and (4) Kentucky Telehealth (“KYTH”), a holding company. Feb. 15 Tr. 73:19-74:17; Feb. 16 Tr. 117:15-118:3; 119:7-11. Bolus is the president,

CEO, and 100% owner of KYTH, which in turn owns 20% of Telehealth. Feb. 16 Tr. 117:15-25; 118:1-13. Bolus is also the president and CEO of Telehealth, which owns 20% of the Debtor. Feb. 16 Tr. 160:20-25. On or about September 5, 2017, shortly after its formation, Curare entered into a Sale Agreement with Solar, [D.E. 137-1], to purchase 80% interest in Bluewater from Solar for an aggregate purchase price of $4,000,000.4 In conjunction with the Sale Agreement, Curare paid Solar $250,000 at closing5 and executed a Term Promissory Note (“Note”), [D.E. 137-2], in favor

of Solar and Bolus in the original principal amount of $3,750,000 for the remaining balance. The Note was secured by a contemporaneous Pledge Agreement, [D.E. 248-15], that Curare executed in favor of Solar which granted Solar a first lien over all of Bluewater’s property and assets as collateral securing Curare’s payment due under the Note. The Note was secured by a Security Agreement executed by Bluewater in favor of Solar, [D.E. 248-16], which granted Solar a security interest in all Bluewater’s business assets and inventory. As part of the sale transaction, Bolus (through KYTH) received a 20% ownership interest in Telehealth, was named president of

4 The acquisition was an owner-financed transaction with $250,000 paid down on the purchase price and the remaining $3.75 million to be paid over time and memorialized via the Note dated September 5, 2017. The Note’s terms required monthly payments—the “greater of (i) the sum of 25% of Bluewater’s cash flow for the immediately preceding month for cash flow up to $100,000.00, plus 50% of the cash flow for any month in excess of $100,000, or (ii) $25,000 .

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Price v. Gurney
324 U.S. 100 (Supreme Court, 1945)
Gray v. Estate of Gray
993 S.W.2d 59 (Court of Appeals of Tennessee, 1998)
In Re Comscape Telecommunications, Inc.
423 B.R. 816 (S.D. Ohio, 2010)
In Re E.S. Bankest, L.C.
321 B.R. 590 (S.D. Florida, 2005)
In Re Orchard at Hansen Park, LLC
347 B.R. 822 (N.D. Texas, 2006)
Matter of Giggles Restaurant, Inc.
103 B.R. 549 (D. New Jersey, 1989)
In Re Flagstaff Foodservice Corp.
29 B.R. 215 (S.D. New York, 1983)
In Re 5877 Poplar, L.P.
268 B.R. 140 (W.D. Tennessee, 2001)
In Re Consolidated Auto Recyclers, Inc.
123 B.R. 130 (D. Maine, 1991)
In Re Player Wire Wheels, Ltd.
421 B.R. 864 (N.D. Ohio, 2009)
In Re Memphis-Friday's Associates
88 B.R. 821 (W.D. Tennessee, 1988)
In Re Avalon Hotel Partners, LLC
302 B.R. 377 (D. Oregon, 2003)
In Re D & W Ltd., LLC
467 B.R. 427 (E.D. Michigan, 2012)
Racing Investment Fund 2000, LLC v. Clay Ward Agency, Inc.
320 S.W.3d 654 (Kentucky Supreme Court, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
Curare Laboratory LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/curare-laboratory-llc-kywb-2022.